2023亚洲专家共识：慢性淋巴细胞白血病的管理

Clinical and Experimental Medicinehttp5/doi.org/10.1007/s10238-023-01007-2CORRESPONDENCEExpert consensus on the management of chronic lymphocyticleukaemia in AsiaEric Tse'.Yok Lam Kwong2.Yeow Tee Goh3.Ping Chong Bee.Soo Chin Ng5.Daryl Tan5.Priscilla Caguioa'.Huynh Nghia.Teresita Dumagay.Lalita Norasetthada10.Suporn Chuncharunee1.Vivek Radhakrishnan12.Bhausaheb Bagal13.Tubagus Djumhana Atmakusuma14.Nadia Ayu Mulansari14Received:4 November 2022 Accepted:18 January 2023©The Author(s)2023AbstractIn recent years,considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia(CLL)dueto the availability of new potent drugs.However,the majority of data on CLL were derived from Western populations,withlimited studies and guidelines on the management of CLL from an Asian population perspective.This consensus guidelineaims to understand treatment challenges and suggest appropriate management approaches for CLL in the Asian populationand other countries with a similar socio-economic profile.The following recommendations are based on a consensus byexperts and an extensive literature review and contribute towards uniform patient care in Asia.Keywords Chronic lymphocytic leukaemia·BTK inhibitors·Bcl-2 inhibitors·Treatment·AsiaIntroductionincidence rate of CLL is approximately 4.92 and 2-6 per100,000 persons per year in Europe and the USA,respec-Chronic lymphocytic leukaemia (CLL)is a clonal maturetively [2,4].The median age of patients at the time ofB-cell neoplasm characterised by lymphocytosis of B-cellsdiagnosis is 71 years,and >95%of CLL patients are overwith a distinct immunophenotype [1].It is the most com-50 years old [2].mon type of leukaemia in adults and accounts for 30%ofThe incidence of CLL is less frequent in individuals ofall leukaemia cases in Western countries [2,3].The annualAsian and Middle Eastern ancestry [2,4].The reported☒Eric Tses Blood Transfusion and Haematology Hospital(BTH).ewctse@hku.hkHo Chi Minh,Vietnam9Division of Haematology,Department of Medicine,Division of Haematology,Medical Oncologyand Haematopoietic Stem Cell Transplant,DepartmentPhilippine General Hospital,Manila,Philippinesof Medicine.School of Clinical Medicine,The University0 Division of Haematology.Department of Internal Medicine,of Hong Kong,Pok Fu Lam,Hong Kong,ChinaFaculty of Medicine,Chiang Mai University,Chiang Mai,2.Division of Haematology,Medical OncologyThailandand Haematopoietic Stem Cell Transplant,Department11Department of Medicine,Ramathibodi Hospital,Mahidolof Medicine,School of Clinical Medicine,The UniversityUniversity,Bangkok,Thailandof Hong Kong,Pok Fu Lam,Hong Kong.China12Clinical Haematology Oncology and HCT,Tata Medical5Department of Haematology,Singapore General Hospital,Centre.Kolkata,IndiaSingapore,Singapore13Department of Medical Oncology,Tata Memorial Centre,Faculty of Medicine,University of Malaya,Kuala Lumpur,Parel,IndiaMalaysia14Haematology-Medical Oncology Division,Dr.Cipto5Subang Jaya Medical Centre (SJMC).S